Immutep announces the first patient has been enrolled and safely dosed in EFTISARC-NEO, the Phase II investigator-initiated trial of eftilagimod alpha, a soluble LAG-3 protein and MHC Class II agonist, in combination with radiotherapy and the anti-PD-1 therapy KEYTRUDA for patients with soft tissue sarcoma. This chemo-free trial is the first to evaluate efti in a neoadjuvant setting. The open-label EFTISARC-NEO Phase II study, which will treat up to 40 patients, is being conducted by the Maria Skodowska-Curie National Research Institute of Oncology and is primarily funded with an approved grant from the Polish government awarded by the Polish Medical Research Agency program.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMMP:
- First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
- Immutep secures third U.S. patent for eftilagimod alpha
- Immutep completes A$80M capital raise
- Immutep granted U.S. patent for IMP761
- Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting